Clinical Trials in Baltimore

Showing 1421-1440 of 11,213 trials

CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults

NCT03970304

This is an open-label, non-randomized study. The purpose of this study is to better understand how vaccines against typhoid fever affect the normal immune system and bacteria in the intestine. Patients having standard-of-care colonoscopies will be divided into 3 groups: Group 1: Vivotif typhoid vaccination then colonoscopy; Group 2: Colonoscopy, then Vivotif typhoid vaccination, then follow-up colonoscopy; Group 3: Colonoscopy without vaccination. The Vivotif typhoid vaccine used in this study is licensed by the Food and Drug Administration (FDA) for travelers to developing countries. Volunteers will be asked to donate tissue, blood, saliva and stool samples for studying how the body responds to the typhoid vaccine.

Typhoid Vaccination

University of Maryland, Baltimore87 participantsStarted Oct 2013

Baltimore, Maryland, United States

Active Not RecruitingPhase 2< 1 mile

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

NCT05287113

The purpose of this study is to evaluate the safety and efficacy of the combination of retifanlimab plus INCAGN02385 and retifanlimab plus INCAGN02385 and INCAGN02390 compared with retifanlimab alone as first-line treatment in PD-L1-positive and systemic therapy-naive recurrent/metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN).

Head and Neck Cancer

Incyte Biosciences International Sàrl176 participantsStarted Nov 2022

Scottsdale, Arizona, United States • Duarte, California, United States • Irvine, California, United States +88 more locations

CVD 37000: Immunity and Microbiome Studies at Intestinal and Systemic Sites in Ty21a Vaccinated Adults

Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

Find Trials by Condition in Baltimore

RewinD-LB - Clinical Study of Neflamapimod in Patients With Dementia With Lewy Bodies

Effect of Dalcetrapib on CV Risk in a Genetically Defined Population With a Recent ACS

A Study of CT-388 in Participants Who Are Overweight or Obese With Type 2 Diabetes Mellitus

A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2

Comparison of Methods of Pulmonary Blood Flow Augmentation in Neonates: Shunt Versus Stent (The COMPASS Trial)

The PLATINUM Trial: Optimizing Chemotherapy for the Second-Line Treatment of Metastatic BRCA1/2 or PALB2-Associated Metastatic Pancreatic Cancer

Safety and Tolerability of IPH4502 in Patients With Advanced Solid Tumors

Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Geographic Atrophy

Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders

SEEG-Guided DBS for OCD

A Study to Check Liver Health in Boys With XLMTM, a Serious Genetic Muscle Condition

International Registry of Intra-arterial and Endosaccular Flow Diverters (IRF)

A Phase 1/2 Study of NRTX-1001 Neuronal Cell Therapy in Drug-Resistant Bilateral Mesial Temporal Lobe Epilepsy (MTLE)

A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With Systemic Lupus Erythematosus

AB154 Combined With AB122 for Recurrent Glioblastoma

Allied Cleft & Craniofacial Quality-Improvement and Research Network (ACCQUIREnet)

[18F]PI-2620 Phase 3 Histopathological Study

Roll-over Study for Patients Who Have Completed a Prior Novartis-sponsored Sabatolimab (MBG453) Study and Are Judged by the Investigator to Benefit From Continued Treatment With Sabatolimab.